JP2024513692A - グレムリン１アンタゴニストを使用して疾患を処置する方法 - Google Patents

グレムリン１アンタゴニストを使用して疾患を処置する方法 Download PDF

Info

Publication number
JP2024513692A
JP2024513692A JP2023555769A JP2023555769A JP2024513692A JP 2024513692 A JP2024513692 A JP 2024513692A JP 2023555769 A JP2023555769 A JP 2023555769A JP 2023555769 A JP2023555769 A JP 2023555769A JP 2024513692 A JP2024513692 A JP 2024513692A
Authority
JP
Japan
Prior art keywords
seq
cancer
grem1
sequence
chain variable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023555769A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024513692A5 (enExample
Inventor
チュー，へ
キアン，シュエミン
ガオ，ウェイキアン
チェン，チャピン
ワン，ジンミン
サン，ディ
Original Assignee
スーチョウ・トランスセンタ・セラピューティクス・カンパニー・リミテッド
シャンハイ ジャオ トン ユニバーシティ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by スーチョウ・トランスセンタ・セラピューティクス・カンパニー・リミテッド, シャンハイ ジャオ トン ユニバーシティ filed Critical スーチョウ・トランスセンタ・セラピューティクス・カンパニー・リミテッド
Publication of JP2024513692A publication Critical patent/JP2024513692A/ja
Publication of JP2024513692A5 publication Critical patent/JP2024513692A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57515—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the breast
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57555—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the prostate
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2023555769A 2021-03-11 2022-03-11 グレムリン１アンタゴニストを使用して疾患を処置する方法 Pending JP2024513692A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
CN2021080142 2021-03-11
CNPCT/CN2021/080142 2021-03-11
CNPCT/CN2022/076516 2022-02-16
CN2022076516 2022-02-16
PCT/CN2022/080297 WO2022188856A1 (en) 2021-03-11 2022-03-11 Method of treating diseases using gremlin1 antagonists

Publications (2)

Publication Number Publication Date
JP2024513692A true JP2024513692A (ja) 2024-03-27
JP2024513692A5 JP2024513692A5 (enExample) 2025-03-19

Family

ID=83226314

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023555769A Pending JP2024513692A (ja) 2021-03-11 2022-03-11 グレムリン１アンタゴニストを使用して疾患を処置する方法

Country Status (11)

Country Link
US (1) US20240190950A1 (enExample)
EP (1) EP4304646A4 (enExample)
JP (1) JP2024513692A (enExample)
KR (1) KR20230156936A (enExample)
CN (1) CN116940380A (enExample)
AU (1) AU2022233762A1 (enExample)
BR (1) BR112023018204A2 (enExample)
CA (1) CA3213121A1 (enExample)
MX (1) MX2023010594A (enExample)
TW (1) TW202300527A (enExample)
WO (1) WO2022188856A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2022207030A1 (en) * 2021-01-18 2023-08-24 Suzhou Transcenta Therapeutics Co., Ltd. Novel anti-gremlin1 antibodies
KR20250169623A (ko) * 2023-04-13 2025-12-03 쑤저우 트랜스센타 테라퓨틱스 컴퍼니 리미티드 암 치료를 위한 grem1 길항제를 수반하는 조합 요법
CN117801109B (zh) * 2024-03-01 2024-05-03 再少年(北京)生物科技有限公司 iPS诱导定向分化成内皮祖细胞的方法及应用
CN119746060B (zh) * 2025-03-07 2025-09-16 南昌大学第一附属医院 一种树突状细胞疫苗制剂及其制备方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019243801A1 (en) * 2018-06-18 2019-12-26 UCB Biopharma SRL Gremlin-1 antagonist for the prevention and treatment of cancer

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013137686A1 (ko) * 2012-03-15 2013-09-19 서울대학교 산학협력단 그렘린-1에 대한 항체
AU2013355260B2 (en) * 2012-12-04 2019-07-25 Caris Mpi, Inc. Molecular profiling for cancer
BR112015021979A2 (pt) * 2013-03-14 2017-08-29 Regeneron Pharma Anticorpos humanos para grem1
WO2017011920A1 (en) * 2015-07-22 2017-01-26 The Royal Institution For The Advancement Of Learning/Mcgill University Compounds and uses thereof in the treatment of cancers and other medical conditions
GB201621635D0 (en) * 2016-12-19 2017-02-01 Ucb Biopharma Sprl Crystal structure
AU2022207030A1 (en) * 2021-01-18 2023-08-24 Suzhou Transcenta Therapeutics Co., Ltd. Novel anti-gremlin1 antibodies

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019243801A1 (en) * 2018-06-18 2019-12-26 UCB Biopharma SRL Gremlin-1 antagonist for the prevention and treatment of cancer

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
LIU, Y. ET AL.: "Knockdown GREM1 suppresses cell growth, angiogenesis, and epithelial-mesenchymal transition in colon", JOURNAL OF CELLULAR BIOCHEMISTRY, vol. 120, no. 4, JPN6026021786, 2019, pages 5583 - 5596, ISSN: 0005872498 *
PARK, S. A. ET AL.: "Gremlin-1 augments the oestrogen-related receptor α signalling through EGFR activation: implication", BRITISH JOURNAL OF CANCER, vol. 123, no. 6, JPN6026021785, 2020, pages 988 - 999, ISSN: 0005872497 *
吾妻 慧一: "前立腺癌治療薬", 薬局, vol. 第72巻, 第1号, JPN6026021787, January 2021 (2021-01-01), pages 165 - 169, ISSN: 0005872499 *

Also Published As

Publication number Publication date
KR20230156936A (ko) 2023-11-15
EP4304646A1 (en) 2024-01-17
CN116940380A (zh) 2023-10-24
TW202300527A (zh) 2023-01-01
BR112023018204A2 (pt) 2023-10-24
WO2022188856A1 (en) 2022-09-15
CA3213121A1 (en) 2022-09-15
MX2023010594A (es) 2023-09-25
US20240190950A1 (en) 2024-06-13
EP4304646A4 (en) 2025-05-28
AU2022233762A1 (en) 2023-10-05

Similar Documents

Publication Publication Date Title
US20240011098A1 (en) Diagnostic and therapeutic methods for cancer
JP7212902B2 (ja) 疾患および障害の処置においてレナラーゼを制御する組成物および方法
WO2022188856A1 (en) Method of treating diseases using gremlin1 antagonists
AU2015313268B2 (en) Cancer-cell-specific antibody, anticancer agent, and cancer testing method
JP2022058699A (ja) 再発性小細胞肺癌の処置方法において使用するための抗ｐｄ－１抗体
CN110546277A (zh) 用于癌症的诊断和治疗方法
CN110650752A (zh) 用于治疗具有NRG1融合基因的细胞的ErbB-2和ErbB3结合双特异性抗体
KR102644658B1 (ko) 모노클로날 항체 항-fgfr4
US10894989B2 (en) Treatment of angiogenesis disorders
JP2023551602A (ja) Ｔｌ１ａを標的とする炎症性疾患の治療のための方法、システム、およびキット
CN112912403A (zh) 治疗肿瘤的方法
CN113396230A (zh) 癌症的诊断和治疗方法
CN112292151A (zh) 抗pd-1抗体在制备治疗实体瘤的药物中的用途
KR20210063330A (ko) 방광암에 대한 치료 및 진단 방법
JP2026083251A (ja) 少なくともｅｇｆｒに結合する抗体を使用した、免疫チェックポイント阻害剤で治療された高いｅｇｆｒ発現を有するがんの治療
CN110139661A (zh) Igfb3及其受体相关疾病的治疗
CN119156228A (zh) 抗tigit抗体及其用途
WO2011007853A1 (ja) 癌特異的アイソフォームに対するモノクローナル抗体
US20180134788A1 (en) Methods and Pharmaceutical Compositions (NTSR1 Inhibitors) for the Treatment of Hepatocellular Carcinomas
WO2023165618A1 (en) Methods for treating cancer
RU2853818C9 (ru) Способ лечения заболеваний с применением антагонистов GREMLIN1
RU2853818C1 (ru) Способ лечения заболеваний с применением антагонистов GREMLIN1
EP4115904A2 (en) Anti-rspo3 antibodies
HK40094175A (en) Method of treating diseases using gremlin1 antagonists
HK40055955A (en) Diagnostic and therapeutic methods for cancer

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250311

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250311

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20260529